Aptevo Therapeutics Inc.
Clinical-stage biotech developing antibody-based immunotherapies for cancer.
APVO | US
Overview
Corporate Details
- ISIN(s):
- US03835L2079
- LEI:
- Country:
- United States of America
- Address:
- 2401 4TH AVE., 98121 SEATTLE
- Website:
- https://aptevotherapeutics.com/
Description
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The company specializes in creating bispecific and trispecific antibody-based therapeutics designed to harness a patient's immune system to fight malignancies. Its pipeline includes multiple candidates targeting both hematologic cancers and solid tumors. The lead candidate, Mipletamig, is a CD3 T-cell engager targeting the CD123 tumor antigen for the treatment of Acute Myeloid Leukemia (AML). Other programs in development target various tumor antigens, including PSMA for prostate cancer and Nectin-4 for solid tumors, utilizing mechanisms like T-cell engagement and co-stimulation to enhance anti-tumor activity.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Aptevo Therapeutics Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Aptevo Therapeutics Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Aptevo Therapeutics Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
